By the 1940s glucagon was being widely used for this purpose in Europe and North America (Unger)
In 2018, the recommendations of the international evidence-based guidelines for the assessment and management of PCOS [1] indicated that, although its use is generally off label, metformin can be considered in addition to lifestyle in women with PCOS and Body Mass Index (BMI) 25 kg/m 2 to potentiate weight loss and to improve endocrine and metabolic outcomes
Both are formulated to address different skin concerns, choose as per your requirement
Whats Next: Regulatory filing for weight management: by end of 2025 Submission for type 2 diabetes: expected in 2026 Drug discovered by Chugai, licensed by Lilly in 2018 Implication: Orforglipron could become the first once-daily oral GLP-1 therapy with potent glucose-lowering and weight-loss benefits, potentially disrupting the injectable incretin market.
A longer-term initiative, the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model , will launch in Medicaid as early as May 2026 and in Medicare Part D by January 2027, combining GLP-1 access with evidence-based lifestyle supports ( [68] )
